Bristol Myers cancer drug meets main goal in late-stage study
Source: SeekingAlpha
2026-03-09 07:28:55 ET
More on Bristol-Myers Squibb Company
- Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Bristol-Myers: I'm Buying Post Earnings
- Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
- FDA plans to relax testing rules to encourage biosimilar drugs: report
- Bristol Myers wins FDA nod to expand label for psoriasis therapy Sotyktu
Read the full article on Seeking Alpha
For further details see:
Bristol Myers cancer drug meets main goal in late-stage study
Bristol-Myers Squibb Company
NASDAQ: BMY
BMY Trading
-1.26% G/L:
$59.845 Last:
3,545,057 Volume:
$60 Open:
BMY Latest News
March 09, 2026 06:59:00 am
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
BMY Stock Data
$123,325,918,376
2,034,328,000
N/A
1394
N/A
Pharmaceuticals
Healthcare
US
Princeton
